Crossmark

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

Crossref DOI link: https://doi.org/10.1186/s40164-018-0101-1

Published Online: 2018-04-13

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mita, Akiko

Abumiya, Maiko

Miura, Masatomo

Niioka, Takenori

Takahashi, Saori

Yoshioka, Tomoko

Kameoka, Yoshihiro

Takahashi, Naoto http://orcid.org/0000-0002-6758-3787
Funding

Funding for this research was provided by:

Japan Society for the Promotion of Science (No. 26927001, No. 26460188, No. 17K08408)
License Information

Text and Data Mining valid from 2018-04-13

Version of Record valid from 2018-04-13
More Information

Article History

Received: 31 January 2018

Accepted: 10 April 2018

First Online: 13 April 2018

Document is current

Any future updates will be listed below